鉴定五个免疫基因模型作为肝细胞癌的独立预后因素。

Identification of a five-immune gene model as an independent prognostic factor in hepatocellular carcinoma.

机构信息

Department of Orthopedic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.

Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.

出版信息

BMC Cancer. 2021 Mar 16;21(1):278. doi: 10.1186/s12885-021-08012-2.

BACKGROUND

Hepatocellular carcinoma (HCC) is a common malignant tumor with a poor prognosis. We aimed to identify a new prognostic model of HCC based on differentially expressed (DE) immune genes.

METHODS

The DE immune genes were identified based on an analysis of 374 cases of HCC and 50 adjacent non-tumor specimens from the Cancer Genome Atlas (TCGA) database. Univariate Cox analysis, Lasso regression, and multivariate Cox analysis were used to construct the model based on the training group. Survival analysis and the receiver operating characteristic (ROC) curves were used to evaluate model performance. The testing group and the entire group were subsequently used for validation of the model.

RESULTS

A five-immune gene model consisted of HSPA4, ISG20L2, NDRG1, EGF, and IL17D was identified. Based on the model, the overall survival was significantly different between the high-risk and low-risk groups (P = 7.953e-06). The AUCs for the model at 1- and 3-year were 0.849 and 0.74, respectively. The reliability of the model was confirmed using the validation groups. The risk score was identified as an independent prognostic parameter and closely related to the content of immune cells from human HCC specimens.

CONCLUSION

We identified a five-immune gene model that can be used as an independent prognostic marker for HCC.

背景

肝细胞癌（HCC）是一种预后较差的常见恶性肿瘤。我们旨在基于差异表达（DE）免疫基因确定 HCC 的新预后模型。

方法

基于癌症基因组图谱（TCGA）数据库中 374 例 HCC 和 50 个相邻非肿瘤标本的分析，确定 DE 免疫基因。使用单因素 Cox 分析、Lasso 回归和多因素 Cox 分析基于训练组构建模型。生存分析和接收者操作特征（ROC）曲线用于评估模型性能。随后使用测试组和整个组验证模型。

结果

确定了由 HSPA4、ISG20L2、NDRG1、EGF 和 IL17D 组成的五个免疫基因模型。基于该模型，高风险和低风险组之间的总体生存率存在显著差异（P=7.953e-06）。模型在 1 年和 3 年的 AUC 分别为 0.849 和 0.74。使用验证组验证了模型的可靠性。风险评分被确定为独立的预后参数，与人类 HCC 标本中免疫细胞的含量密切相关。